Logo image
Transactivation of EGFR by LPS induces COX-2 expression in enterocytes
Journal article   Open access   Peer reviewed

Transactivation of EGFR by LPS induces COX-2 expression in enterocytes

Steven J McElroy, Stuart Hobbs, Michael Kallen, Noemi Tejera, Michael J Rosen, Anatoly Grishin, Poojitha Matta, Claus Schneider, Jeffrey Upperman, Henri Ford, …
PloS one, Vol.7(5), pp.e38373-e38373
2012
DOI: 10.1371/journal.pone.0038373
PMCID: PMC3364993
PMID: 22675459
url
https://doi.org/10.1371/journal.pone.0038373View
Published (Version of record) Open Access

Abstract

Necrotizing enterocolitis (NEC) is the leading cause of gastrointestinal morbidity and mortality in preterm infants. NEC is characterized by an exaggerated inflammatory response to bacterial flora leading to bowel necrosis. Bacterial lipopolysaccharide (LPS) mediates inflammation through TLR4 activation and is a key molecule in the pathogenesis of NEC. However, LPS also induces cyclooxygenase-2 (COX-2), which promotes intestinal barrier restitution through stimulation of intestinal cell survival, proliferation, and migration. Epidermal growth factor receptor (EGFR) activation prevents experimental NEC and may play a critical role in LPS-stimulated COX-2 production. We hypothesized that EGFR is required for LPS induction of COX-2 expression. Our data show that inhibiting EGFR kinase activity blocks LPS-induced COX-2 expression in small intestinal epithelial cells. LPS induction of COX-2 requires Src-family kinase signaling while LPS transactivation of EGFR requires matrix metalloprotease (MMP) activity. EGFR tyrosine kinase inhibitors block LPS stimulation of mitogen-activated protein kinase ERK, suggesting an important role of the MAPK/ERK pathway in EGFR-mediated COX-2 expression. LPS stimulates proliferation of IEC-6 cells, but this stimulation is inhibited with either the EGFR kinase inhibitor AG1478, or the selective COX-2 inhibitor Celecoxib. Taken together, these data show that EGFR plays an important role in LPS-induction of COX-2 expression in enterocytes, which may be one mechanism for EGF in inhibition of NEC.
Cell Line Enterocytes - metabolism Humans Lipopolysaccharides - metabolism Extracellular Signal-Regulated MAP Kinases - metabolism Gene Expression Regulation - drug effects Receptor, Epidermal Growth Factor - metabolism Enterocytes - drug effects Signal Transduction - drug effects Cyclooxygenase 2 - genetics Cyclooxygenase 2 - metabolism Lipopolysaccharides - pharmacology Protein Binding p38 Mitogen-Activated Protein Kinases - metabolism Epidermal Growth Factor - pharmacology Matrix Metalloproteinases - metabolism Enterocytes - enzymology

Details

Metrics

Logo image